{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:18:04Z","timestamp":1791249484610,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,8,14]],"date-time":"2012-08-14T00:00:00Z","timestamp":1344902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2012,8,14]],"date-time":"2012-08-14T00:00:00Z","timestamp":1344902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1038\/leu.2012.229","type":"journal-article","created":{"date-parts":[[2012,8,21]],"date-time":"2012-08-21T11:28:20Z","timestamp":1345548500000},"page":"75-81","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":148,"title":["The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison"],"prefix":"10.1038","volume":"27","author":[{"given":"A K","family":"Burnett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R K","family":"Hills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A E","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Milligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W J","family":"Kell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Wheatley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M F","family":"McMullin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Dignum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N H","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the UK National Cancer Research Institute AML Working Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,8,14]]},"reference":[{"key":"BFleu2012229_CR1","doi-asserted-by":"publisher","first-page":"4417","DOI":"10.1200\/JCO.2011.35.7525","volume":"29","author":"RB Walter","year":"2011","unstructured":"Walter RB, Othus M, Borthakur G, Ravandi F, Cortes-Franco JE, Pierce SA et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol 2011; 29: 4417\u20134423.","journal-title":"J Clin Oncol"},{"key":"BFleu2012229_CR2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1046\/j.1365-2141.1999.01684.x","volume":"107","author":"K Wheatley","year":"1999","unstructured":"Wheatley K, Burnett AK, Goldstone AH, Gray RG, Hann IM, Harrison CJ et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. Brit J Haematol 1999; 107: 69\u201379.","journal-title":"Brit J Haematol"},{"key":"BFleu2012229_CR3","doi-asserted-by":"publisher","first-page":"4606","DOI":"10.1182\/blood-2007-06-096966","volume":"110","author":"ML Sorror","year":"2007","unstructured":"Sorror ML, Giralt S, Sandmaier BM, de Lima M, Shahjahan M, Maloney DG et al. Hematopoietic cell transplantation-specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood 2007; 110: 4606\u20134613.","journal-title":"Blood"},{"key":"BFleu2012229_CR4","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1111\/j.1365-2141.2006.06476.x","volume":"136","author":"FJ Giles","year":"2007","unstructured":"Giles FJ, Borthakur G, Ravandi F, Faderl S, Verstovsek S, Thomas D et al. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol 2007; 136: 624\u2013627.","journal-title":"Br J Haematol"},{"key":"BFleu2012229_CR5","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1016\/S0140-6736(10)62105-8","volume":"376","author":"U Krug","year":"2011","unstructured":"Krug U, Rollig C, Koschmieder A, Heinecke A, Sauerland MC, Schaich M et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet 2011; 376: 2000\u20132008.","journal-title":"Lancet"},{"key":"BFleu2012229_CR6","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","volume":"113","author":"G Juliusson","year":"2009","unstructured":"Juliusson G, Antunovic P, Derolf A, Lehman S, Mollgard L, Stockelberg D et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009; 113: 4179\u20134187.","journal-title":"Blood"},{"key":"BFleu2012229_CR7","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1200\/JCO.1989.7.9.1268","volume":"7","author":"B Lowenberg","year":"1989","unstructured":"Lowenberg B, Zittoun R, Kerkhofs H, Jehn U, Abels J, Debusscher L et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol 1989; 7: 1268\u20131274.","journal-title":"J Clin Oncol"},{"key":"BFleu2012229_CR8","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/j.1365-2141.2009.07604.x","volume":"145","author":"AK Burnett","year":"2009","unstructured":"Burnett AK, Milligan D, Goldstone A, Prentice A, McMullin MF, Dennis M et al. The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. Br J Haematol 2009; 145: 318\u2013332.","journal-title":"Br J Haematol"},{"key":"BFleu2012229_CR9","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1002\/cncr.22496","volume":"109","author":"AK Burnett","year":"2007","unstructured":"Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007; 109: 1114\u20131124.","journal-title":"Cancer"},{"key":"BFleu2012229_CR10","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1200\/JCO.2009.23.3130","volume":"28","author":"HM Kantarjian","year":"2010","unstructured":"Kantarjian HM, Erba HP, Claxton D, Arellano M, Lyons RM, Kovascovics T et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 2010; 28: 549\u2013555.","journal-title":"J Clin Oncol"},{"key":"BFleu2012229_CR11","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1200\/JCO.2009.26.4242","volume":"28","author":"AK Burnett","year":"2010","unstructured":"Burnett AK, Russell NH, Kell J, Dennis M, Milligan D, Paolini S et al. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol 2010; 28: 2389\u20132395.","journal-title":"J Clin Oncol"},{"key":"BFleu2012229_CR12","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1182\/blood-2011-02-337261","volume":"118","author":"RK Hills","year":"2011","unstructured":"Hills RK, Burnett AK . Applicability of a \u2018Pick a Winner\u2019 trial design to acute myeloid leukemia. Blood 2011; 118: 2389\u20132394.","journal-title":"Blood"},{"key":"BFleu2012229_CR13","doi-asserted-by":"publisher","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","volume":"19","author":"EL Sievers","year":"2001","unstructured":"Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001; 19: 3244\u20133254.","journal-title":"J Clin Oncol"},{"key":"BFleu2012229_CR14","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1038\/sj.leu.2402677","volume":"16","author":"RA Larson","year":"2002","unstructured":"Larson RA, Boogaerts MA, Estey E, Karanes C, Stadtmauer EA, Sievers EL et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia 2002; 16: 1627\u20131636.","journal-title":"Leukemia"},{"key":"BFleu2012229_CR15","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1002\/cncr.11791","volume":"98","author":"F Giles","year":"2003","unstructured":"Giles F, Estey E, O\u2019Brien S . Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer 2003; 98: 2095\u20132104.","journal-title":"Cancer"},{"key":"BFleu2012229_CR16","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1182\/blood.V114.22.790.790","volume":"114","author":"S Petersdorf","year":"2009","unstructured":"Petersdorf S, Kopecky K, Stuart RK, Larson RA, Nevill TJ, Stenke L et al. Preliminary results of Southwest Oncology Group Study S0106: an international intergroup phase 3 randomized trial comparing the addition of Gemtuzumab Ozogamicin to standard induction therapy versus post-consolidation Gemtuzumab Ozogamicin versus no additional therapy for previously untreated Acute Myeloid Leukemia. Blood 2009; 114: 326\u2013327, (Abstract).","journal-title":"Blood"},{"key":"BFleu2012229_CR17","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","volume":"29","author":"AK Burnett","year":"2011","unstructured":"Burnett AK, Hills RK, Milligan D, Kjeldsen L, Kell J, Russell NH et al. Identification of patients with Acute Myeloblastic Leukemia who benefit from the addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial. J Clin Oncol 2011; 29: 369\u2013377.","journal-title":"J Clin Oncol"},{"key":"BFleu2012229_CR18","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","volume":"379","author":"S Castaigne","year":"2012","unstructured":"Castaigne S, Pautas C, Terre C, Raffoux E, Bordessoule D, Bastie JN et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 2012; 379: 1508\u20131516.","journal-title":"Lancet"},{"issue":"32","key":"BFleu2012229_CR19","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1200\/JCO.2012.42.2964","volume":"30","author":"Alan K. Burnett","year":"2012","unstructured":"Burnett AK, Russell N, Hills RK, Kell J, Kjeldsen L, Hunter A et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol 2012; e-pub ahead of print 30 July 2012 doi:10.1200\/JCO.2012.42.2964.","journal-title":"Journal of Clinical Oncology"},{"key":"BFleu2012229_CR20","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Wilman CL, Estel EH et al. Revised recommendation of the International Working Group for diagnosis standardisation, of response criteria treatment outcomes and reporting standards for therapeutic trials in acute myeloid leukaemia. J Clin Oncol 2003; 21: 4642\u20134649.","journal-title":"J Clin Oncol"},{"key":"BFleu2012229_CR21","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3816\/CLML.2010.n.033","volume":"10","author":"D Rizzieri","year":"2010","unstructured":"Rizzieri D, LoRusso S, Tse W, Khan K, Advani A, Moore J et al. Phase I study of temozolomide and laromustine (VNP40101M) in patients with relapsed or refractory leukemia. Clin Lymphoma Myeloma Leuk 2010; 10: 211\u2013216.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"BFleu2012229_CR22","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","volume":"28","author":"P Fenaux","year":"2010","unstructured":"Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010; 28: 562\u2013569.","journal-title":"J Clin Oncol"},{"key":"BFleu2012229_CR23","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","volume":"30","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012; 30: 2670\u20132677.","journal-title":"J Clin Oncol"},{"key":"BFleu2012229_CR24","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","volume":"361","author":"HF Fernandez","year":"2009","unstructured":"Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009; 361: 1249\u20131259.","journal-title":"N Engl J Med"},{"key":"BFleu2012229_CR25","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/NEJMoa0901409","volume":"361","author":"B Lowenberg","year":"2009","unstructured":"Lowenberg B, Ossenkoppele GJ, Putten W, Schouten HC, Graux C, Ferrant A et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009; 361: 1235\u20131248.","journal-title":"N Engl J Med"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2012229.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2012229","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2012229.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T15:32:41Z","timestamp":1648740761000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2012229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,14]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["BFleu2012229"],"URL":"https:\/\/doi.org\/10.1038\/leu.2012.229","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,14]]},"assertion":[{"value":"14 June 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2012","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2012","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2012","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AKB has served on advisory boards for Wyeth\/Pfizer during the study. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}